All tauopathies result in various forms of cognitive decline and neuronal loss. Although in some diseases, tau mutations appear to cause neurodegeneration, the toxic "form" of tau remains elusive. Tau is the major protein found within neurofibrillary tangles (NFTs) and therefore it seemed rational to assume that aggregation of tau monomers into NFTs was causal to the disease process. However, the appearance of oligomers rather than NFTs coincides much better with the voluminous neuronal loss in many of these diseases. In this study, we utilized the bigenic mouse line (rTg4510) which conditionally expresses P301L human tau. A novel tau antibody, termed Tau Oligomer Complex 1 (TOC1) was employed to probe mouse brains and assess disease progression. TOC1 selectively recognizes dimers/oligomers and appears to constitute an early stage marker of tau pathology. Its peak reactivity is coincident with other well-known early stage pathological markers such as MC1 and the early-stage phospho-marker CP13. TOC1's reactivity depends on the conformation of the tau species since it does not react with monomer under native conditions, although it does react with monomers under SDS-denaturation. This indicates a conformational change must occur within the tau aggregate to expose its epitope. Tau oligomers preferentially form under oxidizing conditions and within this mouse model, we observe tau oligomers forming at an increased rate and persisting much longer, most likely due to the aggressive P301L mutation. With the help of other novel antibodies, the use of this antibody will aid in providing a better understanding of tau toxicity within Alzheimer's disease and other tauopathies.
Introduction "Tauopathies" are classified as a particular subset of neurodegenerative diseases characterized by a pathological aggregation of hyperphosphorylated tau protein within the human brain. The most well characterized tauopathy is Alzheimer's Disease (AD), while others include Frontotemporal Dementia with Parkinsonism linked to tau on chromosome 17 (FTDP-17-tau; caused by exonic or intronic missense mutations in the tau gene), Picks disease (PiD), Corticobasal Degeneration (CBD), Progressive Supranuclear Palsy (PSP) and Argyrophilic grain disease (AGD) (Arriagada et al., 1992; Ferrer et al., 2008; Gomez-Isla et al., 1997; Iqbal et al., 2005; Lee et al., 2001) . Although the exact mechanism has yet to be elucidated; post-translational modifications, truncations and conformational changes all play a role within this pathological process (Garcia-Sierra et al., 2003) . (See Table 1.) Tau is a microtubule-associated protein (MAP) with limited secondary structure. It is highly soluble and is a major component of the neuronal cytoskeleton (Weingarten et al., 1975) . It exists as six alternatively spliced isoforms in the CNS (Gamblin et al., 2003a; Goedert et al., 1989) . One of tau's normal functions within the neuron may involve ☆☆ The authors would like to thank Dr. Jada Lewis for generously providing the rTg4510 mice for this study. We would like to thank Dr. William Eimer for his assistance with the immunofluorescence experiments. Special acknowledgment: At the time of revisions, Dr. Lester. I. Binder passed away suddenly. Therefore, since this will be the last publication submitted before Dr. Binder's death, the authors would like to specially dedicate this paper to his memory.
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